Paysign, Inc. (PAYS) Earnings Call Transcript & Summary

November 9, 2026

NASDAQ US Financials Financial Services earnings 33 min

Earnings Call Speaker Segments

Mark Newcomer

executive
#1

Thanks, Diego, and good afternoon to all of you. We appreciate you joining Paysign's call covering third quarter 2026 earnings. My name is Mark Newcomer, and I serve as President and Chief Executive Officer. With me today is Jeff Baker, our Chief Financial Officer. We're also joined by Matt Turner, our President of Patient Affordability, along with Matt Lanford, our Chief Payments Officer; both of them will be available during Q&A after our prepared remarks. Earlier today, we released our third quarter results, which showed record revenue, operating income, and adjusted EBITDA. To sum up the quarter, revenue rose 43% year-over-year, reaching $30.8 million. Net income increased more than 200%, hitting $6.7 million, or $0.11 per fully diluted share. Gross margins widened 840 basis points to 64.7%, driven by patient affordability taking a bigger portion of our revenue mix, with that segment up 110% year-over-year. We anticipate both gross and operating margins will keep expanding as patient affordability accounts for a larger share of our revenue mix. Before diving into the details, I'd like to frame this quarter within the broader strategy we've been pursuing. Historically, Paysign has been known as a payment processor mainly focused on the plasma industry. We established a leading position in that business, and it's still a solid one, yet it's a mature market with limited growth, and payment processing is inherently transactional in nature. We set out to add business lines with real growth potential and a more lasting value proposition built on the infrastructure we already had. Patient affordability was the first piece to fill that role. With our products and services, we give pharmaceutical clients value they can measure, helping them sell more and spend less. Just as important, it helps patients start and stay on the therapies they need but might not otherwise be able to pay for; that combination of value for the manufacturer and a good result for the patient is what makes these relationships stick. It also carries more attractive margins. Putting the two together gives us a stronger model, with a cash-generative plasma business alongside a fast-growing, higher-margin business in a large and expanding market. Our strategy is paying off. This quarter's growth, margin improvement, and operating leverage make that clear, and we think it is generating real value for shareholders. Against that backdrop, I want to discuss the plasma customer news included in our release. A customer has informed us that payment processing for 113 of its centers will move to another provider, and that change is expected to finish during the fourth quarter. As we understand it, the customer is folding this business into an existing banking relationship that covers more of its operations. The customer told us the choice wasn't tied to anything about our service, and we're still the processor for a number of that customer's other centers. Third quarter results weren't impacted by this transition, and Jeff will walk you through what we anticipate for the fourth quarter financially. Our plasma business continues to grow. Across the next 2 quarters, we expect new centers from existing clients to make up for losing those centers, and we're currently in active discussions with a couple of prospective new plasma clients. With that said, the quarter's strength was driven primarily by results that beat expectations in our patient affordability business, where revenue grew to $16.6 million, more than doubling year-over-year, and claim volume increased roughly 55%. That shows established programs maturing further, fresh initiatives getting underway, robust usage across those initiatives, and our biggest pharma partnerships scaling up. We likewise lifted revenue per program roughly 32% versus a year earlier, reaching $99,524 — evidence that the programs we bring on are getting deeper as time passes, rather than merely increasing in count. During the third quarter we started 19 new programs, combining brand-new ones with transitions away from other providers, which pushed the platform's total active programs to 167. We anticipate closing out the year with a portfolio of 190 to 195 programs. For 2026, that means we're adding between 59 and 64 programs, compared with 55 programs last year. This expansion shows how much trust pharmaceutical companies have in what we offer, along with the savings we generate for them and for the patients who depend on their therapies. In Q3, roughly $367 million in financial assistance reached patients through our platform. Over the first nine months of 2026, patient benefit delivered now exceeds $1.4 billion, and since the platform's launch, we've supported over $3.2 billion in financial assistance across the programs we administer. What those figures represent is people who are able to begin—and remain on—the therapies they require, many of which are life-saving. The clearest way to gauge the value we provide to our pharma partners is through our dynamic business rules technology. During Q3 by itself, it shielded our clients from roughly $82.5 million in expenses that copay maximizers and accumulator programs would have taken on otherwise. So far this year, that amount exceeds $553 million, and cumulatively since DBR's launch, the savings have gone past $923 million. Those savings explain a great deal about why clients continue to broaden their relationships with us. Regarding industry engagement, Matt Turner participated in an executive panel at the Association for Value-Based Cancer Care Summit, an oncology gathering that draws pharmaceutical companies, prescribers, and other professionals who work directly with patients. Discussion there about copay maximizers and accumulators confirmed what our clients tell us. Our value is being recognized at senior levels within the industry. This November, members of our team will be at the Informa Co-Pay Congress, a key forum for manufacturers, hub partners, and policy leaders focused on patient affordability, and at that event Brian Dennison, our SVP of Sales and Products, will talk about product updates and the new service offerings we plan to launch in 2027. To wrap up, affordability for patients is what powers our growth, and our pipeline is strong and backs the guidance we've given for the balance of the year and on into 2027. Turning to plasma: we posted revenue of $13.8 million, up 7.5% from $12.9 million a year earlier, and the driver was our centers producing more average monthly revenue per center — $8,187 compared with $7,122 — which shows each location is being used more heavily. We closed the quarter serving 562 centers, and we expect to end the year with roughly 445 to 450 centers in service, which mirrors the transition we've been talking about. We're continuing to pursue new plasma business from collection companies that don't currently work with Paysign. Even with the financial hit the transition delivered in the fourth quarter, patient affordability's ongoing momentum gives us the confidence to lift our projections on certain key metrics for year end, and Jeff will walk through those in his prepared remarks. Moving now to Afferion. Afferion is built on everything we've learned as a top processor for plasma centers. We get the pain points these centers deal with, and most of the software they have access to is generic instead of being purpose-built for their industry. Afferion came about in response to those requirements, and in our view it gives the plasma sector — spanning everything from collecting plasma to producing finished goods — a better means of simplifying and managing day-to-day work. The donor management system remains under regulatory evaluation. In-center testing has just been completed, and we submitted those results as part of that review, and we'll share updates as it progresses. Demand for the suite continues to be strong in both the US and the EU; we're expanding our European presence in Dublin through Afferion Technologies Limited, our wholly-owned subsidiary, in order to serve European demand. We also believe Afferion fits the same model that's proven successful for us in patient affordability, with room for better margins and stronger customer relationships. In closing, this quarter is a clear demonstration of us executing well on our growth strategy; we established a leading position in plasma, and we saw the need for further growth opportunities. Patient affordability was the first of those businesses and is now fueling our results through growth, margin expansion, and operating leverage. Our dynamic business rules technology shields our pharmaceutical partners from copay maximizers and accumulators and their associated costs, and behind these figures are patients who are able to begin and remain on the treatments they require. Plasma remains a dependable generator of cash flow, and the know-how we gained serving those customers is what Afferion was founded on. The durability of our core business, together with our belief that we are well placed to capture the opportunities in front of us, gives us confidence that we will continue to produce robust and meaningful year-over-year growth in both revenue and earnings for the foreseeable future. With that, I'll turn things over to Jeff, who will walk you through our third quarter results in more detail.

Jeff Baker

executive
#2

Thank you, Mark, and good afternoon, everyone. We posted another solid quarter. Momentum in patient affordability continued through Q3, and the results reflect that. Revenue, operating margin, and net income each came in above the top end of our guidance, and operating margin grew more than threefold, reaching 23.8%. Total revenues for the third quarter rose 42.6% compared with a year earlier, to $30.8 million. Revenue from the pharma industry led the way, climbing 109.8% year-over-year to $16.6 million. Continued program expansion drove that growth. During the last 12 months, we brought 62 net pharma patient affordability programs live, and we ended the quarter with 167 active programs. Processed claims rose roughly 55% versus the third quarter of 2025. Average quarterly revenue per program came to $99,524 in Q3, compared with $75,435 in the same period a year ago. The revenue gain reflected higher monthly management fees, setup fees, and claims processing fees. It also reflected customer service, contact center support, and other billable services, including dynamic business rules. Plasma revenue grew 7.5% year-over-year, to $13.8 million. Average monthly revenue per center rose 14.9%, to $8,187, from $7,122 in the third quarter of 2025. Stronger utilization at each center primarily drove that improvement. As Mark mentioned, we closed the quarter with 562 centers, consistent with what we communicated on our second quarter earnings call. Gross profit margin widened to 64.7% from 56.3% a year ago. Two factors drove that expansion: a larger mix of pharma revenue, which carries higher gross margins than our plasma business, and slower growth in aggregate costs. Call center support, implementation, processing, and commission costs together grew far below our 42.6% revenue growth. Total operating expenses came in at $12.6 million, up 19.2% from $10.6 million in the third quarter of 2025, also far below our 42.6% revenue growth. Selling, general, and administrative expenses were $10.3 million, up 22.8%, including $1.4 million in stock-based compensation. Operating leverage stands out as one of the quarter's highlights. Operating margin widened to 23.8% from 7.3% in the third quarter of 2025, an improvement of 1,650 basis points. As another indicator of operating leverage, we turned more than $0.60 of every incremental revenue dollar into adjusted operating income. A few other important details for the third quarter: income before taxes rose to $8.2 million from $2.2 million in the third quarter of 2025. The company recorded an income tax provision of $1.5 million. The effective tax rate was 17.8%, versus 1.4% in the third quarter of 2025. That higher rate reflects discrete item adjustments, mainly tied to the increase in our stock price at September 30, 2026, compared with the same period last year. GAAP net income for the quarter was $6.7 million, or $0.11 per fully diluted share, up from $2.2 million, or $0.04 per fully diluted share, in the third quarter of 2025. Adjusted EBITDA rose 118% to $11 million. That compares with $5 million in the third quarter of 2025. Adjusted EBITDA margin widened to 35.7%, up from 23.3% in the same period last year. Adjusted EBITDA is the metric we rely on to assess core operating performance. Stock-based compensation and the change in fair value of contingent consideration are both excluded from this measure. For per share calculations, the fully diluted share count came in at 62.7 million shares, compared with 61.8 million shares a year earlier. We closed the quarter holding $34.5 million of unrestricted cash and carrying no bank debt. On a separate note, restricted cash came to $201.8 million, up $57.9 million from the December 31st, 2025 year end; that growth came mainly from customer program deposits tied to plasma and pharma programs, along with higher funds on card. Funds on card are balances that have been loaded onto cards but that cardholders have not yet spent. As Mark mentioned, a plasma customer of ours is shifting 113 centers to a different provider by the end of the year. Under existing agreements, we continue as processor for several of their remaining centers. Looking at the fourth quarter, we anticipate the transition will lower revenue by $1.5 million and reduce gross profit by $700,000. Across the previous 12 months ending September 2026, those centers accounted for roughly $11.3 million in revenue and $5.15 million in gross profit. Now to our revised full-year 2026 outlook. Revenue, gross profit margin, net income, and adjusted EBITDA each landed comfortably above the top end of the guidance we gave for the third quarter; that momentum, together with the visibility we have into further patient affordability program launches over the rest of this year, leaves us confident we will finish inside our full-year 2026 revenue outlook of $114 million to $117 million while surpassing our earlier full-year margin and profitability outlook, even after factoring in the 113 centers we expect to move to another provider in the fourth quarter; we anticipate full-year gross profit margins of 63.5% to 64.5%, backed by growing patient affordability revenues. GAAP net income should come in at $23 million to $24 million, or $0.37 to $0.38 per diluted share. Adjusted EBITDA is expected at $38.5 million to $40 million. For the full year, we project a tax rate of about 21.3%. On to our operating expectations for year end: we expect to finish the year with 190 to 195 active patient affordability programs and 445 to 450 plasma centers; in short, continued strong momentum in patient affordability programs, higher operating margins versus last year, and a clean balance sheet as we head into the fourth quarter underpin both our full-year outlook and our confidence in the platform's long-term earnings power. That wraps up my prepared remarks. With that, I'll hand the call back to the operator so we can open the question-and-answer session.

Gary Prestopino

analyst
#3

Hi there, good afternoon, everybody. Regarding this plasma business, Mark, you mentioned that you might be adding business next year. I'm just wondering whether there's enough business out there — I don't know if you go about this through RFP or whatever — such that you can replace what losing those centers cost you in terms of revenue and profitability on a run rate basis? My assumption is most of those centers already have somebody processing for them, so you'd really have to pull off some competitive takeaways here.

Mark Newcomer

executive
#4

In answer to your question, Gary, there are absolutely enough centers out there for us to replace what we're losing; it's simply a matter of timing and getting through transitions. Right now we're in discussions with several different organizations.

Gary Prestopino

analyst
#5

All right. Price played no part at all in losing this business. It came down entirely to their need for some sort of banking relationship to back their operations, and the processor that acquired it was able to provide that?

Mark Newcomer

executive
#6

That's right. In the past, we've had customers depart for other banks. This is sort of a pattern that has occurred throughout the historical servicing of these accounts. Banks have come in, and banks have gone out. My expectation is that we won't see much change on that front. Frequently, when these banks arrive, they'll arrive and support things only for a set stretch of time before they wind up leaving once more. Predicting the future is difficult. I don't have a crystal ball for that, but historically that's roughly how it has played out.

Gary Prestopino

analyst
#7

All right. So my final question concerns that. I realize you added staff, and you increased support for the pharma business in general. Did you also need to add staff in order to support the plasma business? What I'd want to ask is whether there are expense cuts that could come from the fact that this business has been lost at an unclear?

Jeff Baker

executive
#8

Hey Gary, yes. Recall that last year, when we won all the centers, we stated we accomplished that with no extra SG&A dollars; now we are losing centers, and bear in mind, this is a highly variable business model; put differently, our costs track the revenues at roughly gross margin. That's 40% to 45% depending on the quarter. There isn't much cost to remove. Perhaps some call center as we see volumes decline again. As Mark alluded to, we feel quite good about the opportunities that exist out there. There are still providers processing with our competitors, and we believe the Afferion software platform will actually help hopefully bring more centers to us over time. Obviously we don't have a crystal ball, but we feel good about the long-term outlook.

Gary Prestopino

analyst
#9

Thank you.

Jeff Baker

executive
#10

Yep.

Jacob Stephan

analyst
#11

Hi everyone, and thanks for taking our questions. To start with patient affordability: the guidance you've given is significantly better than what we anticipated back at the beginning of the year. I'm wondering how you view upcoming program gains, particularly with an eye toward the first half of 2027. And a quick follow-up on that: do you have additional products or solutions that could be cross-sold into your base of 200 programs?

Jeff Baker

executive
#12

I'll handle the first part, then pass it to Matt for that final question. Bear in mind — and this has stayed consistent — 2025, 2026, and even earlier. It's rare to see programs shift during the first half of the year—in fact, the opposite is true. The movement tends to happen later in the year, and that pattern is clearly repeating now. The reason is that when most insurance plans reset on January 1st, everyone wants to be prepared, and they need confidence that their program will be operational by that date. There's no room to switch programs during the busiest stretch of the life cycle. In 2026, meaning this year, I believe we brought on four programs during the first quarter. Occasionally those tie to PDUFA dates or new drug launches, but largely the activity is weighted toward the back end. As we entered this year—and we actually mentioned this—our major conference is Asembia, held every April; once we’re there, we begin to gain clearer insight into the plans our pharmaceutical customers have for the rest of the year. Certain of them remain under contract until various dates across the year, and when those agreements expire, we clearly move those programs across. There are many moving pieces involved in that, which explains why much of the migration occurs in Q3 and Q4. With that said, I’ll hand things over to Matt.

Matt Turner

executive
#13

Hi, Jacob. When you look at the product stack and how it can be used across different clients, we really divide the business into three core verticals: we say we have medical benefit, and then we look at specialty pharmaceutical drugs and retail pharmaceutical drugs. Those are sort of our three key verticals there. Many things are used across all three, and then some things are highly specific to one place or another. Whenever we look at building a product, we try to make it as available to all of our clients as possible. If you look at the IT infrastructure, that's a shared asset, right — it's used across all those different business types. Portals, websites, reporting platforms, BI tools, things like that are all shared because there isn't a huge difference. We might have a different report inside of a system or something, but for the most part, a lot of the tech stack on the back end is used across all three verticals; then anywhere that we can, we develop a product, we want to try to make it, obviously, as profitable as possible, and that means making it as available to as many clients as we can.

Jacob Stephan

analyst
#14

Understood. Perhaps just regarding the Afferion software platform — apologies if this was addressed in the previous question — but is there any news from the FDA? I'm simply wondering whether you have a timeline or anything like that for us.

Matt Turner

executive
#15

At this moment we have no timeline; we're awaiting word from the regulators on that, and the moment we receive it, we'll provide you all with an update.

Jacob Stephan

analyst
#16

All right. Understood. Thanks a lot, everyone. Thank you.

Matt Turner

executive
#17

Thanks.

Jon Hickman

analyst
#18

Hello.

Matt Turner

executive
#19

Hey, John.

Jon Hickman

analyst
#20

Hi there. I'm a bit puzzled. Is the seasonality in your pharma business shifting somewhat? It seems unusual for you to post such a large third quarter compared with Q2.

Matt Turner

executive
#21

Go ahead. Yeah. No, I believe we've discussed this somewhat previously. As we continue bringing on more and more programs, that does obscure the seasonality. Suppose we had no growth this year, right? Say we began the year with 100 programs and finished the year with 100 programs. Then you would see the seasonality. Q1 and Q2 are strong for claims, especially Q1, since everyone's benefits have reset. Moving into Q3 and Q4, claims ramp down, but we're ramping up in business. Normally you'd say, "Oh hey, it appears your claim volume is falling off." That would hold true. Since we're constantly adding more programs in Q3 and Q4, we're pushing up platform utilization, and therefore adding more claims. It obscures the seasonality of the business. Hopefully, that keeps happening.

Jon Hickman

analyst
#22

All right. So here's one more thing I wanted to ask. I realize someone already raised this, but regarding that FDA approval — is there anything they're worried about? Because I think if we'd been talking a year ago, you'd have figured approval would have happened by now.

Matt Turner

executive
#23

That's really not something within our control. There's a question-and-answer phase: they send over a batch of questions, we come back with our answers; they get a set period to go through that, and should further questions come up, they'll send those along too. We've filed everything and at this point we're just waiting.

Jon Hickman

analyst
#24

Alright. Is this your second or third time around with questions?

Matt Turner

executive
#25

Honestly, I’m not in a position to comment on that right now.

Jon Hickman

analyst
#26

Oh, okay. Thank you.

Matt Turner

executive
#27

Thank you.

Gary Prestopino

analyst
#28

I just want to ask about this Afferion platform — I'd assume you're actually out there speaking with prospective clients at the moment. You might have touched on this already, but I'd assume the level of interest is quite high.

Mark Newcomer

executive
#29

There's a great deal of interest. Interest is high in both the US market and the European Union market.

Gary Prestopino

analyst
#30

Okay.

Mark Newcomer

executive
#31

Continues to be.

Gary Prestopino

analyst
#32

So once approval comes through, would it be fair to assume that getting a book of business built up would occur pretty quickly? Or is this a case where you'll still need to bring on one or two of the top plasma centers, whether in the US or Europe, to begin beta testing this product before you're able to take it to market?

Mark Newcomer

executive
#33

Naturally, since we've been spending time working through the review process, we've kept talking with clients. So I believe that removes part of the time you'd otherwise anticipate. I believe our ramp will be faster than expected.

Gary Prestopino

analyst
#34

Okay. Thank you, Mark.

Mark Newcomer

executive
#35

You're very welcome.

Mark Newcomer

executive
#36

Thank you, and I appreciate all of you being here today. I'd like to express gratitude to our employees for their dedication, to our customers and partners for the confidence they place in us, and to our shareholders for their ongoing backing. Our attention stays fixed on making our business stronger, providing dependable service, and putting resources to work wisely with an eye toward what lies ahead; we're eager to share an update with you when we release our fourth quarter and full-year results. Thanks once more, and enjoy the rest of your afternoon.

Operator

operator
#37

This concludes today's conference. All parties may disconnect. Have a good day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Paysign, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Paysign, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Paysign, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.